Sign up for COVID-19 Science UpdatesSection headings in the COVID-19 Science Update have been changed to alignwith the CDC Science Agenda for COVID-19.PDF version for this update pdf icon[PDF – 1 MB]Here you can find all previous COVID-19 Science Updates.: Phase 2/3 safety and efficacy study of a SARS-CoV-2 spike protein mRNA vaccine candidate previously reported by Walsh et al.external icon was assessed for a median of two months.
Healthy persons ≥16 years old were randomly assigned 1:1 to receive two intramuscular doses of 30 μg placebo (n = 21,728) or BNT162b2 (n = 21,720) 21 days apart and followed for development of symptoms in which case they underwent viral testing for SARS-CoV-2.